Aromatase inhibition alters vascular reactivity and arterial compliance in men: a possible vascular role for endogenous sex hormones in males.
Explore the source record for details and available documents.
Acetylcholine↗
Biomedical subjects
J W Funder
Publications and source records attributed to J W Funder.
15-Hydroxyprostaglandin dehydrogenase: Cinderella meets Prince Serendip.
Explore the source record for details and available documents.
Animals↗
Telomerase is controlled by protein kinase Calpha in human breast cancer cells.
Telomerase, a specialized RNA-directed DNA polymerase that extends telomeres of eukaryotic chromosomes, is repressed in human somatic tissues and becomes activated during tumor progression in most human cancers. To date, little is known about how telomerase is activated and controlled in cancer, although activation is thought to be involved in cancer cell immortalization. Here, we report that human telomerase-associated protein 1 (hTEP1) and the telomerase catalytic subunit (human telomerase reverse transcriptase (hTERT)) are phosphoproteins and that their phosphorylation is a prerequisite for the activation of telomerase in intact human breast cancer cells. Identified by hTEP1 peptide affinity chromatography, protein kinase Calpha mediates the phosphorylation of hTEP1 and hTERT and induces a marked increase in telomerase activity. Thus, phosphorylation of hTEP1 and hTERT by protein kinase Calpha represents an essential step in the generation of a functional telomerase complex in the initiation and maintenance of telomerase activity in human cancer.
Amino Acid Sequence↗
Differential regulation of MAP kinase activity by corticotropin-releasing hormone in normal and neoplastic corticotropes.
Corticotropin-releasing hormone (CRH) plays an important role in regulating the development and function of hypothalamic-pituitary-adrenal axis. The mechanisms by which CRH regulates tissue-specific growth, differentiation and gene expression remain to be established. In the present study, we show that CRH differentially regulates MAP kinase activity in normal ovine anterior pituitary cells and mouse corticotrope AtT20 cells. Incubation of ovine normal anterior pituitary cells with CRH increased MAP kinase activity, an effect mimicked by cAMP and inhibited by the protein kinase A inhibitor H89. In contrast, incubation of mouse pituitary tumor AtT20 cells with CRH inhibited MAP kinase activity, an effect also mimicked by forskolin and inhibited by H89. This decrease in MAP kinase activity occurred with a time course similar to the increase seen in normal anterior pituitary cells. Furthermore, both effects of CRH on MAP kinase activity were inhibited by atrial natriuretic peptide (ANP). ANP also reversed the inhibition of DNA synthesis induced by CRH in AtT20 cells. Thus, CRH may differentially regulate cell growth in sheep normal anterior pituitary and mouse tumor corticotropes by modulating MAP kinase activity through a mechanism dependent on cAMP production and subject to regulation by ANP.
8-Bromo Cyclic Adenosine Monophosphate↗
Aldosterone action: fact, failure and the future.
1. It is now 45 years since aldosterone was isolated and 25 years since its genomic action, via mineralocorticoid receptors (MR), was first described. 2. Although the classic physiological role of aldosterone is to promote unidirectional transepithelial sodium transport, our ignorance of the mechanisms involved remains profound. 3. Unanswered questions include: (i) the physiological significance of the equivalent, high affinity of MR for aldosterone, progesterone, corticosterone and cortisol; (ii) the protein(s) induced as a direct transcriptional response to aldosterone; (iii) the physiological roles of MR in non-epithelial tissues where aldosterone, in concert with salt loading, produces direct pathophysiological effects; (iv) how aldosterone occupies epithelial MR, despite the 100-fold 'advantage' it enjoys over cortisol/corticosterone due to transcortin binding/11 beta-hydroxysteroid dehydrogenase activity, as plasma glucocorticoid levels are approximately 2000-fold higher; and (v) how epithelial MR, normally overwhelmingly occupied by glucocorticoids, are not transcriptionally active under normal circumstances in vivo, in contrast with transfection systems or the syndrome of apparent mineralocorticoid excess. 4. Possible avenues for consideration of the last two of these questions are briefly proposed.
11-beta-Hydroxysteroid Dehydrogenases↗
Effects of estrogen and estrous cycle on glucocorticoid and catecholamine responses to stress in sheep.
There have been relatively few studies of the effects of estrogen on hormonal responses to stress. We therefore studied changes in ACTH, cortisol, norepinephrine (NE), and epinephrine (Epi) after stress induced by a barking dog (audiovisual stressor) and insulin-induced hypoglycemia (metabolic stressor) in ovariectomized sheep treated with estradiol or placebo and in intact sheep in the follicular and luteal phases of the estrous cycle. Both stressors produced acute increases in ACTH, cortisol, Epi, and NE. A high physiological dose of estradiol significantly reduced the ACTH and cortisol responses to both stressors but did not affect Epi and NE responses. Plasma ACTH and cortisol responses to both stressors and Epi and NE responses to insulin were lower in the follicular than in the luteal phase, but catecholamine responses to the audiovisual stressor did not change during the estrous cycle. We conclude that in sheep, estrogen attenuates glucocorticoid responses to stress and that hormonal changes during the estrous cycle affect glucocorticoid responses to both metabolic and audiovisual stressors and catecholamine responses to a metabolic stressor.
Adrenocorticotropic Hormone↗
Examination of genotype and phenotype relationships in 14 patients with apparent mineralocorticoid excess.
Apparent mineralocorticoid excess (AME) is a genetic disorder causing pre- and postnatal growth failure, juvenile hypertension, hypokalemic metabolic alkalosis, and hyporeninemic hypoaldosteronism due to a deficiency of 11 beta-hydroxysteroid dehydrogenase type 2 enzyme activity (11 beta HSD2). The 11 beta HSD2 enzyme is responsible for the conversion of cortisol to the inactive metabolite cortisone and therefore protects the mineralocorticoid receptors from cortisol intoxication. Several homozygous mutations are associated with this potentially fatal disease. We have examined the phenotype, biochemical features, and genotype of 14 patients with AME. All of the patients had characteristic signs of a severe 11 beta HSD2 defect. Birth weights were significantly lower than those of their unaffected sibs. The patients were short, underweight, and hypertensive for age. Variable damage of one or more organs (kidneys, retina, heart, and central nervous system) was found in all of the patients except one. The follow-up studies of end-organ damage after 2-13 yr of treatment in six patients demonstrated significant improvement in all patients. The urinary metabolites of cortisol demonstrated an abnormal ratio with predominance of cortisol metabolites, i.e. tetrahydrocortisol plus 5 alpha-tetrahydrocortisol/tetrahydrocortisone was 6.7-33, whereas the normal ratio is 1.0. Infusion of [11-3H]cortisol resulted in little release of tritiated water, indicating the failure of the conversion of cortisol to cortisone. Thirteen mutations in the HSD11B2 gene have been previously published, and we report three new genetic mutations in two patients, one of whom was previously unreported. All of the patients had homozygous defects except one, who was a compound heterozygote. Our first case had one of the most severe mutations, resulting in the truncation of the enzyme 11 beta HSD2, and died at the age of 16 yr while receiving treatment. Three patients with identical homozygous mutations from different families had varying degrees of severity of clinical and biochemical features. Due to the small number of patients with identical mutations, it is difficult to correlate genotype with phenotype. In some cases, early and vigilant treatment of AME patients may prevent or improve the morbidity and mortality of end-organ damage such as renal or cardiovascular damage and retinopathy. The outcome of treatment in more patients may establish the efficacy of treatment.
Adolescent↗
Positive and negative discrimination of estrogen receptor agonists and antagonists using site-specific DNA recombinase fusion proteins.
Activation of the estrogen receptor (ER) by hormone involves at least two steps. First, hormone binding initially relieves repression, a property imposed on ER in cis by its ligand-binding domain (EBD). Subsequently, the derepressed ER binds specific genomic sites and regulates transcription. In addition to the natural hormone, ER binds a broad range of ligands that evoke a spectrum of responses ranging from full ER activation by agonists to partial activation and inhibition by partial or complete antagonists. How these different ligands evoke different ER responses remains unclear. To address this issue, we have developed a nontranscriptional assay for ER ligand responsiveness based on Flp recombinase/human EBD protein chimeras. These fusion proteins transduce the transient event of ligand binding into a permanent DNA change in a human cell line system. A fusion protein including ER D, E, and F domains was activated by all the ER ligands tested, demonstrating that both agonists and antagonists serve to relieve initial repression, and that differences between them lie downstream in the activation pathway. Mutant variants of the Flp-ER protein that distinguish between agonists and antagonists, and a mutant EBD that selectively lost the ability to respond to 17beta,-estradiol but not to other ligands, were also identified. Thus, agonists and antagonists can be functionally distinguished in a nontranscriptional assay.
DNA Nucleotidyltransferases↗
Protein phosphatase 2A inhibits nuclear telomerase activity in human breast cancer cells.
Most cancer cells have increased levels of telomerase activity implicated in cell immortalization. Activation of telomerase, a ribonucleoprotein complex, catalyzes the elongation of the ends of mammalian chromosomal DNA (telomeres), the length of which regulates cell proliferation. Currently, how telomerase is regulated in cancer is not yet established. The present study shows that telomerase activity is regulated by protein phosphorylation in human breast cancer cells. Incubation of cell nuclear telomerase extracts with protein phosphatase 2A (PP2A) abolished the telomerase activity; in contrast cytoplasmic telomerase activity was unaffected, and protein phosphatases 1 and 2B were ineffective. Inhibition of telomerase activity by PP2A was both concentration- and time-dependent and was prevented by the protein phosphatase inhibitor okadaic acid. In addition, nuclear telomerase inhibited by PP2A was reactivated by endogenous protein kinase(s) in the presence of ATP, but not in the presence of ATPgammaS. Furthermore, telomerase activity in cultured human breast cancer PMC42 cells was stimulated by okadaic acid, consistent with a role for PP2A in the regulation of telomerase activity in intact cells. These findings suggest that protein phosphorylation reversibly regulates the function of telomerase and that PP2A is a telomerase inhibitory factor in the nucleus of human breast cancer cells.
Breast Neoplasms↗
Glucocorticoid and mineralocorticoid receptors: biology and clinical relevance.
Mineralocorticoid and glucocorticoid receptors act as homodimers via canonical pentadecamer hormone response elements to regulate transcription. Glucocorticoid, but as yet not mineralocorticoid, receptors have been shown also to modulate AP-1- and NF kappa B-induced transcription by direct protein-protein interactions. The role of 11 beta-hydroxysteroid dehydrogenase in conferring aldosterone specificity on epithelial mineralocorticoid receptors has been proven by the demonstration of sequence mutations in all cases of apparent mineralocorticoid excess examined to date. The autosomal form of aldosterone resistance (pseudohypoaldosteronism) has been shown to reflect loss-of-function mutations in epithelial sodium channel subunit sequence. (Patho)physiological roles for aldosterone and glucocorticoid membrane receptors, and for the recently described nuclear receptors for 11-ketosteroids in 11 beta-hydroxysteroid dehydro-genase-protected epithelia, remain to be established.
Aldosterone↗
Aldosterone rapidly represses protein kinase C activity in neonatal rat cardiomyocytes in vitro.
Aldosterone lowers protein kinase C (PKC) activity in myocyte-enriched cultures from neonatal Sprague-Dawley rat hearts, with activity measured by the transfer of phosphate to myristolated alanine-rich C-kinase substrate, in the presence of Ca2+, phosphatidylserine, and diolein. The effect is rapid, with a significant effect after 1 min exposure, half maximal at < or = 1 nM aldosterone, with steroids showing a hierarchy of potency aldosterone = 9alpha fluorocortisol > deoxycorticosterone > corticosterone > spironolactone. Both Ca2+-dependent and -independent PKC activity appear equally inhibited by aldosterone, and PMA-stimulated increases in PKC activity appear similarly aldosterone-sensitive. No displaceable binding of [3H]aldosterone to purified PKC can be shown, evidence against a direct effect of aldosterone on PKC; aldosterone does not alter basal or PMA-stimulated PKC activity in cardiac fibroblasts, evidence for a cell-specific mediator of the myocyte effect. Taken with the previous demonstration of the potentiation of aldosterone-specific MR-mediated effects by PKC activation, the present data argue for the existence of a complex cross-talk mechanism between aldosterone and factors affecting PKC activity in the heart.
Aldosterone↗
Mineralocorticoid receptors, salt, and hypertension.
This review, covering work from the Baker Institute and elsewhere, is divided into four sections. In the first a summary account of two areas-mineralocorticoid receptors and the enzyme 11 beta hyderoxysteroid dehydrogenase-will be given as background. Next is a brief consideration of the three single-gene causes of human hypertension described to date-glucocorticoid-remediable aldosteronism. Liddle's syndrome, and apparent mineralocorticoid excess-in all of which abnormal sodium handling is a feature. Third, the sequelae of aldosterone occupancy of nonepithelial mineralocorticoid receptors will be analyzed in some detail by reviewing studies on experimental mineralocorticoid hypertension and cardiac fibrosis from this laboratory and elsewhere. Finally, three recent studies from this laboratory will be presented: on putative 11-ketosteroid receptors in epithelial tissue, on glucose-PKC potentiation of mineralocorticoid effects on heart cells, and on the necessity for factors/ processes other than the conversion of cortisol to cortisone (or, in the rat, corticosterone to 11-dehydrocorticosterone) to ensure aldosterone-specific effects in mineralocorticoid target tissues.
11-beta-Hydroxysteroid Dehydrogenases↗
Rat 11 beta-hydroxysteroid dehydrogenase type 2 enzyme is expressed at low levels in the placenta and is modulated by adrenal steroids in the kidney.
The 11 beta-hydroxysteroid dehydrogenase type II enzyme (11 beta HSD2) protects the non-discriminating mineralocorticoid receptor from occupation by glucocorticoids. In man the enzyme is also highly expressed in the placenta where it is thought to also protect the fetus from the high circulating levels of maternal glucocorticoids. Mutations in the HSD11B2 gene have recently been shown to account for the syndrome of apparent mineralocorticoid excess. In the present study we have used a rat 11 beta HSD2 cDNA to study the distribution and regulation of this enzyme. The rat protein is highly homologous to the mouse, rabbit and human enzymes, except for the carboxy-terminal region which displays extensive divergence between species beyond residue 382. Northern blot analysis of rat total RNA showed that the single copy gene is highly expressed in kidney and adrenal with lower levels in the colon; surprisingly, there was no detectable signal in the placenta. There was also no detectable mRNA in the liver, heart, hippocampus, testis, thymus and pancreas. Nuclease protection analysis revealed the presence of moderate 11 beta HSD2 message levels in the parotid and exceedingly low levels in the placenta. Regulation studies showed that administration of dexamethasone, deoxycorticosterone and 9 alpha-fluorocortisol to adrenalectomized rats for 7 days increased renal enzyme activity 33%-50%, while message levels decreased 35%-70%, suggesting that the increased enzyme activity may represent activation of latent enzyme.
11-beta-Hydroxysteroid Dehydrogenases↗
Point mutations abolish 11 beta-hydroxysteroid dehydrogenase type II activity in three families with the congenital syndrome of apparent mineralocorticoid excess.
The 11 beta-hydroxysteroid dehydrogenase type II enzyme (11 beta HSD2) converts cortisol into mineralocorticoid receptor inactive cortisone, thus preventing occupation of the non-selective mineralocorticoid receptor by glucocorticoids in the kidney. Mutations generating inactive enzymes have been described in the HSD11B2 gene in the congenital syndrome of apparent mineralocorticoid excess (AME), although proof of mutant protein synthesis was not provided. In the present study we have examined the metabolism of cortisol in mammalian cells transfected with plasmids expressing the wild type and mutant enzymes from three additional families of patients with mutations in the HSD11B2 gene. These studies revealed that the mutants were enzymatically inactive in intact mammalian cells expressing significant levels of both full length and truncated proteins. This is the first study to definitively show that point mutations in the HSD11B2 gene abolish 11 beta HSD2 enzymatic activity in the syndrome of AME.
11-beta-Hydroxysteroid Dehydrogenases↗
Mineralocorticoids, salt, hypertension: effects on the heart.
In uninephrectomized rats on 1% NaCl solution to drink, aldosterone (0.75 micrograms/h subcutaneously for 8 weeks) raises blood pressure and causes marked interstitial and perivascular cardiac fibrosis, effects not seen in animals on a low salt intake. In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-angiotensin systems, as fibrosis is largely unaffected by concurrent administration of Losartan or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the mineralocorticoid receptor (MR) antagonist RU28318; (v) is via classical MR, in that it is blocked by concurrent administration of the MR antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting. Although there is a high probability that the action of aldosterone to cause cardiac fibrosis in this experimental model is an effect via non-epithelial MR, the locus of aldosterone action remains to be established, as do the molecular mechanisms linking MR occupancy by aldosterone and collagen deposition. In addition, and in particular, the mechanisms underlying the crucial contribution of high salt intake in this model of mineralocorticoid excess await exploration.
Aldosterone↗
Mineralocorticoid receptors in the central nervous system.
"Mineralocorticoid receptors (MR) in the central nervous system" is something of a misnomer, in that the sites so designated almost certainly act predominantly as high affinity receptors for glucocorticoid hormones in most areas of the brain, reflecting the equivalent affinity of MR for aldosterone, corticosterone and cortisol. In epithelial tissues, the enzyme 11 beta hydroxysteroid dehydrogenase-2 confers aldosterone-specificity on the otherwise non-selective MR, by converting physiologic glucocorticoids (but not aldosterone) to receptor-inactive 11-keto metabolites. Coding differences in guinea-pig ACTH and glucocorticoid receptors produce very high circulating free cortisol levels; guinea-pig MR have nonetheless similar high affinity for aldosterone and glucocorticoids as those in the rat, evidence for the lack of evolutionary drive towards lower affinity MR, and for an "always occupied" mode of action of CNS MR. Whether these "always occupied" MR act at composite response elements, by the formation of heterodimers with GR or other transcription factors, or by binding progesterone in the luteal phase, in pregnancy and in utero, remains to be established.
Animals↗
Mineralocorticoid receptors and glucocorticoid receptors.
Explore the source record for details and available documents.
11-beta-Hydroxysteroid Dehydrogenases↗
Progesterone binding to mineralocorticoid receptors: in vitro and in vivo studies.
In previous studies using expressed recombinant human mineralocorticoid receptors (MR), progesterone was reported to have widely divergent affinity, from approximately 10 nM to < 10 pM. In the present studies, cytosol preparations of colon or hippocampus were incubated with [3H]aldosterone or [3H]progesterone, alone or with excess RU-486, and the ability of each steroid to compete for MR was determined. In guinea pigs, progesterone has equivalent affinity to aldosterone for MR in vitro, and in rats three times of that aldosterone, with no differences between tissues. In vivo, in both epithelial (kidney, colon) and nonepithelial tissues (heart, hippocampus), progesterone was 10- to 100-fold less potent a competitor than aldosterone for MR, both in the absence of transcortin (8-day-old rats) and in adult mice. Bolus injection of [3H]progesterone was not specifically bound in any of the four tissues. Whether progesterone at steady state may bid for MR occupancy under conditions of high circulating free levels (in utero, luteal phase, pregnancy), presumably to act as an antagonist to cortisol/corticosterone in unprotected nonepithelial receptors, thus remains to be determined.
Adrenalectomy↗